16,019 Shares in Legend Biotech Co. (NASDAQ:LEGN) Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D bought a new position in shares of Legend Biotech Co. (NASDAQ:LEGNGet Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 16,019 shares of the company’s stock, valued at approximately $654,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American International Group Inc. purchased a new position in shares of Legend Biotech in the 2nd quarter worth about $33,000. Nomura Holdings Inc. purchased a new position in shares of Legend Biotech in the 2nd quarter worth about $215,000. National Pension Service boosted its holdings in shares of Legend Biotech by 428.8% in the 2nd quarter. National Pension Service now owns 4,992 shares of the company’s stock worth $275,000 after purchasing an additional 4,048 shares in the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Legend Biotech by 65.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,274 shares of the company’s stock worth $290,000 after purchasing an additional 2,079 shares in the last quarter. Finally, abrdn plc purchased a new position in shares of Legend Biotech in the 2nd quarter worth about $295,000. 38.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Evercore ISI assumed coverage on Legend Biotech in a report on Tuesday, November 1st. They issued an “outperform” rating for the company. UBS Group began coverage on Legend Biotech in a report on Tuesday, December 6th. They set a “buy” rating and a $66.00 target price for the company. Guggenheim began coverage on Legend Biotech in a report on Monday, October 31st. They set a “neutral” rating for the company. Cowen began coverage on Legend Biotech in a report on Tuesday, November 1st. They set an “outperform” rating for the company. Finally, Piper Sandler increased their target price on Legend Biotech from $72.00 to $78.00 and gave the company an “overweight” rating in a report on Tuesday, December 20th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $67.71.

Legend Biotech Price Performance

LEGN opened at $54.23 on Monday. The business has a 50 day simple moving average of $51.13 and a two-hundred day simple moving average of $48.03. The firm has a market capitalization of $8.90 billion, a price-to-earnings ratio of -45.57 and a beta of -0.13. Legend Biotech Co. has a one year low of $30.75 and a one year high of $57.72.

Legend Biotech Profile

(Get Rating)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.

Read More

Institutional Ownership by Quarter for Legend Biotech (NASDAQ:LEGN)

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.